A comparative study of the myeloprotective effect of dicarbamine and leucostim in experimental post-radiation bone marrow syndrome]

We studied the effect of dicarbamine and leucostim on myelopoiesis in experimental post-radiation bone marrow syndrome. Dicarbamine in different modes of administration and doses provided a high level of protection of proliferating hematopoietic precursors in the early period after radiation, which was reflected in a statistically significant decrease in the depth and duration of post-radiation deficit of cells, such as of granulocytes, lymphocytes, megakaryocytes and erythroid cells. The greatest effect of the drug appeared at a dose of 4 mg/kg (prophylactic administration) and a dose of 15 mg/kg (curative double dose). In the bone marrow of experimental animals leucostim prevented development of post-radiation deficit of granulocytes and lymphocytes to a lesser extent, than dicarbamine, and it was effective for erythroid cells and megakaryocytes.